Abstract

The anticancer activity of acridone derivatives has attracted increasing interest, therefore, a variety of substituted analogs belonging to this family have been developed and evaluated for their anti-cancer properties. A series of N-alkyl-acridones 1–6 and N,N′-dialkyl-9,9′-biacridylidenes 7–12 with variable alkyl chains were examined for their topoisomerase I activity at neutral and acidic conditions as well as for their binding capacity to calf thymus and possible radical trapping antioxidant activity. It was found that at a neutral pH, topoisomerase I activity of both classes of compounds was similar, while under acidic conditions, enhanced intercalation was observed. N-alkyl-acridone derivatives 1–6 exhibited stronger, dose-dependent, cytotoxic activity against MCF-7 human breast epithelial cancer cells than N,N′-dialkyl-9,9′-biacridylidenes 7–12, revealing that conjugation of the heteroaromatic system plays a significant role on the effective distribution of the compound in the intracellular environment. Cellular investigation of long alkyl derivatives against cell migration exhibited 40–50% wound healing effects and cytoplasm diffusion, while compounds with shorter alkyl chains were accumulated both in the nucleus and cytoplasm. All N,N′-dialkyl-9,9′-biacridylidenes showed unexpected high scavenging activity towards DPPH or ABTS radicals which may be explained by higher stabilization of radical cations by the extended conjugation of heteroaromatic ring system.

Highlights

  • Acridone derivatives have been applied in clinics as anti-tumor chemotherapeutics since the1970s

  • ethidium bromide (EtBr) exposure, the intercalation of the planar cationic molecule into a supercoiled plasmid induces complete relaxation of negatively supercoiled (SC) DNA resulting in a slower DNA migration pattern through the agarose medium (0.5 μM)

  • The present study identified the topoisomerase I unwinding activity, DNA binding properties, and cytotoxic activity against MCF-7 breast cells of a series of N-alkylacridones and N,N0 -dialkyl-9,90 -biacridylidenes substituted with varying alkyl chains

Read more

Summary

Introduction

Acridone derivatives have been applied in clinics as anti-tumor chemotherapeutics since the1970s. Acridone derivatives have been applied in clinics as anti-tumor chemotherapeutics since the. The cytotoxicity of acridone and acridine-based compounds arise from their direct binding to DNA and from interactions with specific biological targets [1]. Additional telomerase and protein-kinase inhibitory activity may contribute to cytotoxic effects in cancer treatment [2]. Analogs with a 2,20 -bis-pyridyl group substituted on the acridone scaffold or with a tetracyclic acridone structures, named as zanthacridones, showed broad antitumor activity against numerous cancer cell lines [3]. Derivatives with terminal ammonium substituents at C2 and C7 positions on the acridone moiety showed significant activity against leukemia CCRF-CEM cells along with limited toxic effect against normal cells proliferation [4]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call